Cogent Biosciences
Biotechnology, 275 Wyman Street, Waltham, , 2451, Massachusetts, United States, 51-200 Employees
Phone Number: 61********
Who is COGENT BIOSCIENCES
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging va...
Read More
-
Headquarters: 275 Wyman Street, Waltham, Massachusetts, 2451, United States
-
Date Founded: 2014
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from COGENT BIOSCIENCES
Cogent Biosciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Cogent Biosciences
Answer: Cogent Biosciences's headquarters are located at 275 Wyman Street, Waltham, , 2451, Massachusetts, United States
Answer: Cogent Biosciences's phone number is 61********
Answer: Cogent Biosciences's official website is https://cogentbio.com
Answer: Cogent Biosciences's revenue is $25 Million to $50 Million
Answer: Cogent Biosciences's SIC: 2836
Answer: Cogent Biosciences's NAICS: 541714
Answer: Cogent Biosciences has 51-200 employees
Answer: Cogent Biosciences is in Biotechnology
Answer: Cogent Biosciences contact info: Phone number: 61******** Website: https://cogentbio.com
Answer: Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogents lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month